Renaissance Technologies LLC Acquires 45,200 Shares of Cardiovascular Systems Inc (NASDAQ:CSII)
Renaissance Technologies LLC lifted its holdings in shares of Cardiovascular Systems Inc (NASDAQ:CSII) by 4.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,180,100 shares of the medical device company’s stock after buying an additional 45,200 shares during the period. Renaissance Technologies LLC owned approximately 3.39% of Cardiovascular Systems worth $50,662,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Altshuler Shaham Ltd bought a new position in Cardiovascular Systems during the 2nd quarter valued at about $28,000. Advisor Group Inc. boosted its holdings in Cardiovascular Systems by 88.8% in the second quarter. Advisor Group Inc. now owns 655 shares of the medical device company’s stock worth $28,000 after purchasing an additional 308 shares during the last quarter. Personal Wealth Partners purchased a new stake in Cardiovascular Systems in the second quarter worth approximately $78,000. BerganKDV Wealth Management LLC bought a new stake in Cardiovascular Systems in the 1st quarter worth approximately $155,000. Finally, Janus Henderson Group PLC bought a new stake in Cardiovascular Systems in the 1st quarter worth approximately $232,000. Institutional investors own 90.36% of the company’s stock.
A number of research firms have weighed in on CSII. BidaskClub downgraded Cardiovascular Systems from a “buy” rating to a “hold” rating in a report on Wednesday, September 4th. Zacks Investment Research downgraded Cardiovascular Systems from a “hold” rating to a “strong sell” rating and set a $47.00 price target for the company. in a research note on Thursday, August 8th. Needham & Company LLC reissued a “hold” rating on shares of Cardiovascular Systems in a report on Wednesday, August 7th. Stifel Nicolaus lowered shares of Cardiovascular Systems from a “buy” rating to a “hold” rating and boosted their target price for the company from $41.00 to $45.00 in a research report on Tuesday, July 16th. They noted that the move was a valuation call. Finally, Lake Street Capital boosted their target price on shares of Cardiovascular Systems from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. Cardiovascular Systems currently has an average rating of “Hold” and an average price target of $48.50.
Cardiovascular Systems (NASDAQ:CSII) last announced its quarterly earnings data on Tuesday, August 6th. The medical device company reported $0.04 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.04. Cardiovascular Systems had a negative return on equity of 0.18% and a negative net margin of 0.10%. The company had revenue of $68.23 million during the quarter, compared to the consensus estimate of $66.04 million.
In related news, insider Sandra Sedo sold 882 shares of Cardiovascular Systems stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $47.06, for a total transaction of $41,506.92. Following the sale, the insider now owns 51,357 shares of the company’s stock, valued at approximately $2,416,860.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Alexander Rosenstein sold 6,308 shares of the business’s stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $50.42, for a total value of $318,049.36. Following the completion of the transaction, the general counsel now directly owns 78,187 shares in the company, valued at $3,942,188.54. The disclosure for this sale can be found here. Over the last three months, insiders sold 8,326 shares of company stock valued at $412,994. Corporate insiders own 2.80% of the company’s stock.
About Cardiovascular Systems
Cardiovascular Systems, Inc, a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral, Predator 360, Stealth 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral, Diamondback 360 2.00 Peripheral, Diamondback 360 200cm Peripheral, and Diamondback 360 180cm Peripheral, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives.
Further Reading: Quiet Period Expirations
Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.